Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAR443820 in Multiple Sclerosis
NCT05630547Phase 2Terminated
- Sponsor
- Sanofi
- Start
- Dec 2022
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 2, randomised, double-blind trial in multiple sclerosis (MS) comparing SAR443820 with Placebo (2 arms). Primary endpoint: Serum Neurofilament Light Chain at 72 weeks. Started Dec 2022; status: terminated.
02
Drugs
oditrasertib
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT05630547.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05630547.